SRPT - Sarepta Therapeutics, Inc.
NEXT EARNINGS:
Feb 25, 2026
(today)
EPS Est: $-0.71
|
Rev Est: $391.0M
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$21.57
DETAILS
HIGH:
$32.00
LOW:
$15.00
MEDIAN:
$20.00
CONSENSUS:
$21.57
UPSIDE:
14.49%
Market Cap:
1.97B
Volume:
2,499,590
Avg Volume:
2,851,141
52 Week Range:
10.42-109.55
Sector:
Healthcare
Industry:
Biotechnology
Beta:
0.39
Last Dividend:
$N/A
Exchange:
NASDAQ
Country:
US
Employees:
1,372
IPO Date:
1997-06-04
EPS (TTM):
2.47
P/E Ratio:
49.14
Revenue (TTM):
1.90B
Total Assets:
3.96B
Total Debt:
1.34B
Cash & Equiv:
1.10B
Rev Growth (5Y):
37.9%
EPS Growth (5Y):
N/A
FCF Growth (5Y):
N/A
ROCE:
8.6%
Debt/Equity:
0.88
Earnings History
| Date | EPS Actual | EPS Est | EPS Surprise | Rev Actual | Rev Est | Rev Surprise |
|---|---|---|---|---|---|---|
| 2025-11-03 | $-0.13 | $0.01 | -1400.0% | $399.4M | $391.4M | +2.0% |
| 2025-08-06 | $2.02 | $1.11 | +82.0% | $611.1M | $342.9M | +78.2% |
| 2025-05-06 | $-3.42 | $0.35 | -1077.1% | $744.9M | $739.6M | +0.7% |
| 2025-02-26 | $1.50 | $1.38 | +8.7% | $658.4M | $631.0M | +4.3% |
| 2024-11-06 | $0.62 | $-0.06 | +1139.7% | $467.2M | $407.2M | +14.7% |
| 2024-08-07 | $0.07 | $0.01 | +1201.1% | $362.9M | $394.4M | -8.0% |
| 2024-05-01 | $0.73 | $0.10 | +625.6% | $413.5M | $379.5M | +8.9% |
| 2024-02-28 | $0.47 | $0.01 | +3084.3% | $396.8M | $385.8M | +2.8% |
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.90B | 1.24B | 933.01M | 701.89M | 540.10M | 380.83M | 301.03M | 154.58M | 5.42M | 1.25M | 9.76M | 14.22M |
| Net Income | 235.24M | (535.98M) | (703.49M) | (418.78M) | (554.13M) | (715.08M) | (361.92M) | (50.69M) | (267.26M) | (220.03M) | (135.79M) | (111.98M) |
| EPS | 2.47 | -5.80 | -8.03 | -5.15 | -7.11 | -9.71 | -5.46 | -0.86 | -5.49 | -5.20 | -3.39 | -3.31 |
| Total Assets | 3.96B | 3.26B | 3.13B | 3.15B | 2.98B | 1.82B | 1.64B | 1.31B | 424.10M | 273.78M | 295.03M | 291.57M |
| Total Debt | 1.34B | 1.40B | 1.62B | 1.15B | 1.09B | 737.47M | 420.55M | 431.05M | 16.15M | 23.40M | 6.33M | 1.67M |
| Cash & Equivalents | 1.10B | 428.43M | 966.78M | 2.12B | 1.50B | 835.08M | 370.83M | 599.69M | 122.42M | 80.30M | 73.55M | 256.96M |
| Operating Cash Flow | (205.79M) | (500.99M) | (325.35M) | (443.17M) | 107.47M | (456.46M) | (388.66M) | (232.00M) | (245.82M) | (149.47M) | (128.54M) | (64.69M) |
| Free Cash Flow | (342.74M) | (588.34M) | (357.60M) | (481.66M) | 25.26M | (516.09M) | (453.00M) | (253.21M) | (252.69M) | (154.30M) | (155.36M) | (68.47M) |
| FCF per Share | -3.60 | -6.37 | -4.08 | -5.93 | 0.32 | -7.01 | -6.84 | -4.30 | -5.19 | -3.65 | -3.88 | -2.02 |
| Book Value | 1.53B | 859.34M | 384.95M | 928.01M | 761.76M | 818.19M | 1.03B | 789.22M | 336.69M | 190.35M | 247.65M | 247.19M |
| Cash & ST Investments | 1.35B | 1.68B | 1.99B | 2.12B | 1.94B | 1.12B | 1.17B | 1.08B | 317.85M | 192.49M | 210.34M | 256.96M |
| ROC Equity | 0.15 | -0.62 | -1.83 | -0.45 | -0.73 | -0.87 | -0.35 | -0.06 | -0.79 | -1.16 | -0.55 | -0.45 |